Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 2
1949 1
1950 2
1951 2
1952 8
1953 3
1954 4
1955 3
1956 5
1957 5
1958 4
1959 3
1961 1
1962 3
1963 3
1964 2
1965 4
1967 3
1968 2
1969 2
1971 2
1972 2
1974 6
1975 1
1976 5
1977 1
1979 2
1980 1
1982 2
1984 1
1985 1
1986 2
1987 8
1988 2
1989 3
1990 4
1991 5
1992 7
1993 5
1994 2
1995 4
1996 7
1997 4
1998 4
1999 5
2000 6
2001 3
2002 4
2003 4
2004 4
2005 2
2006 4
2007 15
2008 9
2009 10
2010 12
2011 17
2012 31
2013 29
2014 12
2015 14
2016 21
2017 9
2018 17
2019 12
2020 14
2021 17
2022 19
2023 21
2024 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

413 results

Results by year

Filters applied: . Clear all
Page 1
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V; PROTECT Investigators. Heerspink HJL, et al. Lancet. 2023 May 13;401(10388):1584-1594. doi: 10.1016/S0140-6736(23)00569-X. Epub 2023 Apr 1. Lancet. 2023. PMID: 37015244 Clinical Trial.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.
Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J; STOP-IgAN Investigators. Rauen T, et al. N Engl J Med. 2015 Dec 3;373(23):2225-36. doi: 10.1056/NEJMoa1415463. N Engl J Med. 2015. PMID: 26630142 Free article. Clinical Trial.
Outcomes of a Delirium Prevention Program in Older Persons After Elective Surgery: A Stepped-Wedge Cluster Randomized Clinical Trial.
Deeken F, Sánchez A, Rapp MA, Denkinger M, Brefka S, Spank J, Bruns C, von Arnim CAF, Küster OC, Conzelmann LO, Metz BR, Maurer C, Skrobik Y, Forkavets O, Eschweiler GW, Thomas C; PAWEL Study Group. Deeken F, et al. JAMA Surg. 2022 Feb 1;157(2):e216370. doi: 10.1001/jamasurg.2021.6370. Epub 2022 Feb 9. JAMA Surg. 2022. PMID: 34910080 Free PMC article. Clinical Trial.
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis.
EVOLVE Trial Investigators; Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. EVOLVE Trial Investigators, et al. N Engl J Med. 2012 Dec 27;367(26):2482-94. doi: 10.1056/NEJMoa1205624. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121374 Free article. Clinical Trial.
After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.
Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Budde K, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J; STOP-IgAN Investigators. Rauen T, et al. Kidney Int. 2020 Oct;98(4):1044-1052. doi: 10.1016/j.kint.2020.04.046. Epub 2020 May 22. Kidney Int. 2020. PMID: 32450154 Free article. Clinical Trial.
Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia.
Guedes M, Muenz DG, Zee J, Bieber B, Stengel B, Massy ZA, Mansencal N, Wong MMY, Charytan DM, Reichel H, Waechter S, Pisoni RL, Robinson BM, Pecoits-Filho R; CKDopps Investigators. Guedes M, et al. Among authors: reichel h. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030. doi: 10.1681/ASN.2020101531. Epub 2021 Jul 8. J Am Soc Nephrol. 2021. PMID: 34244326 Free PMC article.
[Acetabular cup replacement].
Reichel H, Fuchs M. Reichel H, et al. Orthopade. 2021 Oct;50(10):832-834. doi: 10.1007/s00132-021-04146-0. Epub 2021 Sep 2. Orthopade. 2021. PMID: 34476542 German. No abstract available.
413 results